160 related articles for article (PubMed ID: 34225008)
21. Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.
Byun JS; Singhal SK; Park S; Yi DI; Yan T; Caban A; Jones A; Mukhopadhyay P; Gil SM; Hewitt SM; Newman L; Davis MB; Jenkins BD; Sepulveda JL; De Siervi A; Nápoles AM; Vohra NA; Gardner K
Clin Cancer Res; 2020 Apr; 26(8):1905-1914. PubMed ID: 31911546
[TBL] [Abstract][Full Text] [Related]
22. Unraveling the regulatory connections between two controllers of breast cancer cell fate.
Lee J; Tiwari A; Shum V; Mills GB; Mancini MA; Igoshin OA; Balázsi G
Nucleic Acids Res; 2014 Jun; 42(11):6839-49. PubMed ID: 24792166
[TBL] [Abstract][Full Text] [Related]
23. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
24. Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer.
Akbari V; Kallhor M; Akbari MT
J Cell Biochem; 2019 Jan; 120(1):575-583. PubMed ID: 30125992
[TBL] [Abstract][Full Text] [Related]
25. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
McCune K; Mehta R; Thorat MA; Badve S; Nakshatri H
Oncol Rep; 2010 Nov; 24(5):1233-9. PubMed ID: 20878115
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H
Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169
[TBL] [Abstract][Full Text] [Related]
27. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
Wen W; Chen Z; Bao J; Long Q; Shu XO; Zheng W; Guo X
Nat Commun; 2021 Sep; 12(1):5318. PubMed ID: 34518541
[TBL] [Abstract][Full Text] [Related]
28. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation at enhancers identifies distinct breast cancer lineages.
Fleischer T; Tekpli X; Mathelier A; Wang S; Nebdal D; Dhakal HP; Sahlberg KK; Schlichting E; ; Børresen-Dale AL; Borgen E; Naume B; Eskeland R; Frigessi A; Tost J; Hurtado A; Kristensen VN
Nat Commun; 2017 Nov; 8(1):1379. PubMed ID: 29123100
[TBL] [Abstract][Full Text] [Related]
30. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer.
Lacroix M; Leclercq G
Mol Cell Endocrinol; 2004 Apr; 219(1-2):1-7. PubMed ID: 15149721
[TBL] [Abstract][Full Text] [Related]
31. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
33. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
34. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
35. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
36. Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor α gene through GATA-binding protein 3 (GATA3).
Qi J; Huo L; Zhu YT; Zhu YJ
J Biol Chem; 2014 Nov; 289(45):31373-81. PubMed ID: 25258321
[TBL] [Abstract][Full Text] [Related]
37. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G; Chhangawala S; Cocco E; Razavi P; Cai Y; Otto JE; Ferrando L; Selenica P; Ladewig E; Chan C; Da Cruz Paula A; Witkin M; Cheng Y; Park J; Serna-Tamayo C; Zhao H; Wu F; Sallaku M; Qu X; Zhao A; Collings CK; D'Avino AR; Jhaveri K; Koche R; Levine RL; Reis-Filho JS; Kadoch C; Scaltriti M; Leslie CS; Baselga J; Toska E
Nat Genet; 2020 Feb; 52(2):198-207. PubMed ID: 31932695
[TBL] [Abstract][Full Text] [Related]
38. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.
Laganière J; Deblois G; Lefebvre C; Bataille AR; Robert F; Giguère V
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11651-6. PubMed ID: 16087863
[TBL] [Abstract][Full Text] [Related]
39. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
40. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer.
Wolf I; Bose S; Williamson EA; Miller CW; Karlan BY; Koeffler HP
Int J Cancer; 2007 Mar; 120(5):1013-22. PubMed ID: 17163418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]